DEA Pushes 20 Percent Reduction in Opioid Manufacturing

(CN) – The U.S. Drug Enforcement Administration on Friday proposed a 20 percent reduction in opioid narcotic manufacturing next year.


The DEA said it is proposing to reduce more commonly prescribed opioid painkillers, including oxycodone, hydrocodone, oxymorphone, hydromorphone, morphine, codeine, meperidine and fentanyl. The agency said demand for these medicines has dropped, as awareness has increased of the dangers of opioid addiction.

“Physicians, pharmacists and patients must recognize the inherent risks of these powerful medications, especially for long-term use,” acting DEA administrator Chuck Rosenberg said. “More states are mandating use of prescription drug monitoring programs, and that has prompted a decrease in opioid prescriptions.”

The DEA and its federal partners have increased efforts in the last several years to educate practitioners, pharmacists, manufacturers, and the public about the dangers associated with the misuse of opioid medications and the importance of properly prescribing, the DEA said. Last year, the U.S. Centers for Disease Control and Prevention issued guidelines on opioid use to health care practitioners recommending a reduction in prescribing opioid medications for chronic pain, the DEA said.

The DEA may initiate quotas on the manufacturing of controlled substances. The quota system was intended to reduce or eliminate diversion from legitimate channels of trade by controlling the quantities of the basic ingredients needed for the manufacture of controlled substances, the DEA said.

The purpose of quotas, the DEA said, is to provide an adequate supply for legitimate medical use of schedule I and schedule II controlled substances, which have a high potential for abuse, while limiting the amounts available to prevent diversion.

DEA must balance the production of what is needed for legitimate use against making too much of these potentially harmful substances, the agency said. DEA establishes quotas for more than 250 controlled substances annually.

In setting its quotas, the DEA considers data from the U.S. Food and Drug Administration; estimates of retail consumption based on prescriptions dispensed; manufacturers’ forecasts and other data.

#story_page_ below_article

Understand the importance of honest news ?

So do we.

The past year has been the most arduous of our lives. The Covid-19 pandemic continues to be catastrophic not only to our health - mental and physical - but also to the stability of millions of people. For all of us independent news organizations, it’s no exception.

We’ve covered everything thrown at us this past year and will continue to do so with your support. We’ve always understood the importance of calling out corruption, regardless of political affiliation.

We need your support in this difficult time. Every reader contribution, no matter the amount, makes a difference in allowing our newsroom to bring you the stories that matter, at a time when being informed is more important than ever. Invest with us.

Make a one-time contribution to Alternet All Access, or click here to become a subscriber. Thank you.

Click to donate by check.

DonateDonate by credit card
Donate by Paypal

Don't Sit on the Sidelines of History. Join Alternet All Access and Go Ad-Free. Support Honest Journalism.